Abstract: A heterologous expression cassette, DNA construct and vaccine composition for immunization against flavivirus and/or other pathogens. DNA constructs, recombinant viruses and vaccine compositions containing the recombinant viruses were obtained. This invention also concerns and provide an improved expression vector of the live-attenuated yellow fever 17D virus. Modifications in the expression cassette of heterologous proteins in the intergenic E/NS1 region of the yellow fever 17D vaccine virus, were made. The two new functional domains inserted in the expression cassette were (1) a coding sequence for the N-glycosylation motif, located between the NS1 N-terminal motif and the heterologous protein and (2) a sequence which promoted the proteolytic cleavage, or not, of the recombinant protein in such a way as to release it from its C-terminal containing the transmembrane domains and, consequently, from its association with the membrane of the endoplasmatic reticulum—ER.
Type:
Grant
Filed:
August 4, 2017
Date of Patent:
January 25, 2022
Assignee:
FUNDAÇÃO OSWALDO CRUZ
Inventors:
Myrna Cristina Bonaldo, Noemia Santana Lima
Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Middle East Respiratory Syncytial Coronavirus (MERS-CoV) viral antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an MERS-CoV virus infection in a subject using said composition and method of generation.
Type:
Grant
Filed:
September 27, 2018
Date of Patent:
January 25, 2022
Assignees:
THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, INOVIO PHARMACEUTICALS, INC.
Inventors:
David Weiner, Trevor R F Smith, Kar Muthumani
Abstract: The present invention relates to the field of protein purification. In particular, the invention concerns methods for increasing the filtration capacity of virus filters, by combined use of endotoxin removal and cation-exchange media in the prefiltration process.
Abstract: Novel nanoparticle fusion proteins comprising proteins or peptides fused to Dps (DNA binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products.
Abstract: Provided are an ORF7 deficient varicella virus, an vaccine comprising the virus and use thereof, as well as a method for the production the virus.
Type:
Grant
Filed:
April 13, 2020
Date of Patent:
January 11, 2022
Assignees:
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Rutgers, The State University of New Jersey, Xiamen University
Abstract: Some embodiments provided herein relate to combined assays. In some embodiments, an assay for identifying influenza type A or influenza type B is combined with an assay for determining the sensitivity of an influenza neuraminidase to an antiviral drug.
Type:
Grant
Filed:
April 15, 2019
Date of Patent:
December 28, 2021
Assignee:
Becton, Dickinson and Company
Inventors:
Robert Campbell, Kevin G. Dolan, Eric Fallows, Randal A. Hoke, Ross Jacobson, J. Bruce Pitner, Glenn P. Vonk, Rajashaker Kache, Upma Gulati, Herman D. Himel, IV, Rosemary B. Evans-Storms
Abstract: Isolated peptides comprising one or more antigenic sites of filovirus glycoprotein and methods of their use and production are disclosed. Nucleic acid molecules encoding the peptides are also provided. In several embodiments, the peptides can be used to induce an immune response to filovirus glycoprotein, such as Zaire ebolavirus glycoprotein, in a subject, for example, to treat or prevent infection of the subject with the virus.
Type:
Grant
Filed:
October 31, 2017
Date of Patent:
December 21, 2021
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Abstract: A Dengue virus Envelope Dimer Epitope (EDE) wherein the EDE: c) spans the polypeptides of a Dengue virus Envelope polypeptide dimer; and/or d) is presented on a dimer of Envelope proteins; and/or c) is formed from consecutive or non-consecutive residues of the envelope polypeptide dimer, wherein the dimer is a homodimer or heterodimer of native and/or mutant envelope polypeptides, from any one or two of DENV-1, DENV-2, DENV-3 and DENV-4.
Type:
Grant
Filed:
July 23, 2015
Date of Patent:
December 14, 2021
Assignees:
IMPERIAL COLLEGE INNOVATIONS LIMITED, INSTITUT PASTEUR, UNIVERSITE PARIS-SACLAY
Inventors:
Screaton Gavin, Juthathip Mongkolsapaya, Alexander Rouvinski, Pablo Guardado-Calvo, Giovanna Barba-Spaeth, Stéphane Duquerroy, Marie-Christine Vaney, Felix Augusto Rey
Abstract: Described herein are methods and compositions for vaccination against influenza. The compositions comprise recombinant engineered influenza hemagglutinin polypeptides. Also disclosed are methods of producing recombinant engineered influenza hemagglutinin polypeptides in cell-based systems.
Abstract: Novel, nanoparticle-based vaccines are provided that elicit an immune response to a broad range of infectious agents, such as influenza viruses. The nanoparticles comprise a heterogeneous population of fusion proteins, each comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to one or more immunogenic portions of a protein from an infectious agent, such as influenza virus. The fusion proteins self-assemble to form nanoparticles that display a heterogeneous population of immunogenic portions on their surface. When administered to an individual, such nanoparticles elicit an immune response to different strains, types, subtypes and species with in the same taxonomic family. Thus, such nanoparticles can be used to vaccinate an individual against infection by different Types, subtypes and/or strains of infectious agents.
Type:
Grant
Filed:
December 31, 2015
Date of Patent:
December 7, 2021
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Barney S. Graham, Masaru Kanekiyo, Hadi M. Yassine
Abstract: The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus. In one embodiment, an antibody or binding fragment according to the invention is capable of binding to and/or neutralizing one or more influenza A virus group 1 subtypes selected from H1, H2, H5, H6, H8, H9, H11, H12, H13, H16 and H17 and variants thereof and one or more influenza A virus group 2 subtype selected from H3, H4, H7, H1, 0, H14 and H15 and variants thereof.
Type:
Grant
Filed:
October 8, 2019
Date of Patent:
November 30, 2021
Assignees:
MEDIMMUNE, LLC, HUMABS BIOMED SA
Inventors:
Ebony Benjamin, Nicole Kallewaard-LeLay, Josephine Mary McAuliffe, Frances Palmer-Hill, Leslie Wachter, Andy Yuan, Qing Zhu, Davide Corti, Antonio Lanzavecchia, Barbara Guarino, Anna DeMarco
Abstract: The present invention relates to killed/inactivated and/or recombinant Senecavirus A immunogenic compositions and vaccines, and methods of preventing or treating animals in need of with such an immunogenic compositions and vaccines.
Type:
Grant
Filed:
July 9, 2018
Date of Patent:
November 23, 2021
Inventors:
Arun V. Iyer, Abby Rae Patterson, Joseph Gilbert Victoria, Eric Martin Vaughn, Luis Alejandro Hernandez, Jennifer L. English
Abstract: The present invention provides an anticancer agent containing the following (1) and (2): (1) HVJ-E (hemagglutinating virus of Japan envelope), (2) an inhibitor of an immune checkpoint protein.
Abstract: The invention provides methods and compositions for eliciting broad immune responses. The methods employ nucleic acid vaccines that encodes highly conserved elements from a virus.
Type:
Grant
Filed:
August 28, 2019
Date of Patent:
November 9, 2021
Assignees:
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Inventors:
George Pavlakis, Barbara Felber, James Mullins
Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.
Type:
Grant
Filed:
April 12, 2019
Date of Patent:
November 2, 2021
Assignees:
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., CORNELL RESEARCH FOUNDATION, INC., THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION
Inventors:
Patti Cynthia Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, Nancy J. Cox, William L. Castleman
Abstract: The present invention provides system and methods for detecting an analyte indicative of an influenza viral infection in a sample of bodily fluid. The present invention also provides for systems and method for detection a plurality of analytes, at least two of which are indicative of an influenza viral infection in a sample of bodily fluid.
Abstract: The present invention generally relates to an immunogenic construct, useful for redirecting an EBV-existing immune response towards an undesired target cell and/or microorganism, to methods for preparing said conjugate, to a pharmaceutical applications comprising said conjugate, and to medical applications thereof.
Type:
Grant
Filed:
December 15, 2016
Date of Patent:
October 19, 2021
Assignees:
Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université de Paris, Institut National Transfusion Sanguine
Abstract: Disclosed herein is an anti-DENV antibody, a pharmaceutical composition comprising the same, and uses thereof. According to embodiments of the present disclosure, the anti-DENV antibody comprises a heavy chain variable region and a light chain variable region, in which the heavy chain variable region comprises amino acid sequences of SEQ ID NOs: 1-3, and the light chain variable region comprises amino acid sequences of SEQ ID NOs: 5-7.
Type:
Grant
Filed:
May 22, 2018
Date of Patent:
October 12, 2021
Assignees:
NATIONAL CHENG KUNG UNIVERSITY, DCB-USA LLC
Inventors:
Trai-Ming Yeh, Yung-Chun Chuang, Yen-Chung Lai